LifeSci Capital Initiates Coverage On Crescent Biopharma with Outperform Rating, Announces Price Target of $22
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
LifeSci Capital analyst Charles Zhu initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Outperform rating and announces Price Target of $22.
LifeSci Capital analyst Charles Zhu initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Outperform rating and announces Price Target of $22.